GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Cyclically Adjusted FCF per Share

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Cyclically Adjusted FCF per Share : $-11.44 (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-1.236. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-11.44 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -7.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -7.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Inovio Pharmaceuticals was 23.40% per year. The lowest was -9.00% per year. And the median was 8.80% per year.

As of today (2024-06-09), Inovio Pharmaceuticals's current stock price is $9.59. Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-11.44. Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.42 -9.18 -10.17 -10.91 -11.28

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.06 -11.14 -11.17 -11.28 -11.44

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.236/131.7762*131.7762
=-1.236

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.757 100.560 -2.302
201409 -1.656 100.428 -2.173
201412 -1.627 99.070 -2.164
201503 -2.481 99.621 -3.282
201506 -1.710 100.684 -2.238
201509 2.376 100.392 3.119
201512 -1.260 99.792 -1.664
201603 -2.728 100.470 -3.578
201606 -2.629 101.688 -3.407
201609 -3.109 101.861 -4.022
201612 -2.425 101.863 -3.137
201703 -2.587 102.862 -3.314
201706 -3.463 103.349 -4.416
201709 -2.880 104.136 -3.644
201712 -1.965 104.011 -2.490
201803 -1.821 105.290 -2.279
201806 -2.563 106.317 -3.177
201809 -3.220 106.507 -3.984
201812 -2.201 105.998 -2.736
201903 -4.075 107.251 -5.007
201906 -2.937 108.070 -3.581
201909 -3.253 108.329 -3.957
201912 -1.658 108.420 -2.015
202003 -2.465 108.902 -2.983
202006 -2.094 108.767 -2.537
202009 -5.130 109.815 -6.156
202012 -3.587 109.897 -4.301
202103 -3.147 111.754 -3.711
202106 -4.505 114.631 -5.179
202109 -2.662 115.734 -3.031
202112 -2.171 117.630 -2.432
202203 -3.392 121.301 -3.685
202206 -2.577 125.017 -2.716
202209 -3.247 125.227 -3.417
202212 -1.740 125.222 -1.831
202303 -1.716 127.348 -1.776
202306 -1.468 128.729 -1.503
202309 -1.300 129.860 -1.319
202312 -1.156 129.419 -1.177
202403 -1.236 131.776 -1.236

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Inovio Pharmaceuticals  (NAS:INO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Headlines